Please ensure Javascript is enabled for purposes of website accessibility
Home / News / KC Daily Record / Amgen gets High Court review of fraud suit

Amgen gets High Court review of fraud suit

The U.S. Supreme Court will decide whether investors must prove that misinformation from Amgen Inc. propped up its stock price before they can pursue a class-action stock-fraud suit against the world’s largest biotechnology company.

Leave a Reply

Your email address will not be published. Required fields are marked *

*